FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Grigoriadis Dimitri E.</u>					2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [NBIX]							BIX (Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify				
NEUROCRINE BIOSCIENCES, INC. 12790 EL CAMINO REAL				0	3. Date of Earliest Transaction (Month/Day/Year) 02/27/2008								Vice President, Research				
(Street) SAN DIEGO CA 92130 (City) (State) (Zip)				4	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line					
		Ta	ble I - Non-D	erivati	ve Se	curities	s Ac	quired, D	ispo	sed o	f, or Be	neficially	Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,		Code (Instr.		ed (A) or tr. 3, 4 and 5	5. Amoun Securities Beneficia Owned Fo	s lly ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
						Code V	, A	Amount	ınt (A) or (D)		Transacti (Instr. 3 a	tion(s)			(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any			4. Transa Code 8)		Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expi Date	oiration e	Title	Amount or Number of Shares		(Instr. 4))II(S)		
Stock Option ⁽¹⁾	\$5.12	02/27/2008		A		30,000		02/27/2009	02/2	27/2015	Common Stock	30,000	\$5.12	30,000		D	
Restricted Stock Units	(2)	02/27/2008		A		100,000		(3)		(3)	Common Stock	100,000	\$0	100,000	0	D	

Explanation of Responses:

- 1. Represents option of which 1/3 of the shares underlying the option becomes vested and exercisable on February 27, 2009, February 27, 2010 and February 27, 2011, respectively.
- 2. Each restricted stock unit represents a contingent right to receive one share of Neurocrine Common Stock.
- 3. The restricted stock units will vest annually at 1/3 of the units vesting on March 27, 2009, February 27, 2010, and February 27, 2011, respectively.

Remarks:

Margaret E. Valeur-Jensen, By

** Signature of Reporting Person Date

02/29/2008

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.